Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabotegravir

FDA-approved product (suspension, extended release, intramuscular), marketed as Apretude, Vocabria.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cabotegravir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Integrase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AJ04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabotegravir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabotegravir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

    NCT02354937 · start 2015-07-13

    Registered record
    Registry ID
    NCT02354937
    Conditions
    Infection, Human Immunodeficiency Virus; HIV Infections
    Interventions
    GSK1265744 30 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-07-13
    Completion
    2016-11-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus; HIV Infections
    InterventionGSK1265744 30 mg
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects

    NCT02159131 · start 2014-08

    Registered record
    Registry ID
    NCT02159131
    Conditions
    Infections, Human Immunodeficiency Virus and Hepatitis
    Interventions
    Ethinyl Estadiol; Levonorgestrel; GSK1265744
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-08
    Completion
    2014-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Human Immunodeficiency Virus and Hepatitis
    InterventionEthinyl Estadiol; Levonorgestrel; GSK1265744
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

    NCT02076178 · start 2014-03-27

    Registered record
    Registry ID
    NCT02076178
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    744 Tablet; 744 LA Injection; Placebo Tablet; Placebo Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03-27
    Completion
    2016-02-23
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    Intervention744 Tablet; 744 LA Injection; Placebo Tablet; Placebo Injection
    PhasePhase 2
    Registry statusCompleted

  • Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

    NCT01641809 · start 2012-08-06

    Registered record
    Registry ID
    NCT01641809
    Conditions
    Infection, Human Immunodeficiency Virus; HIV Infections
    Interventions
    GSK1265744 10 mg; GSK1265744 30 mg; GSK1265744 60 mg; Efavirenz 600 mg; Rilpivirine 25 mg; Placebo; Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08-06
    Completion
    2019-01-15
    Enrolment
    244

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus; HIV Infections
    InterventionGSK1265744 10 mg; GSK1265744 30 mg; GSK1265744 60 mg; Efavirenz 600 mg +3 more
    PhasePhase 2
    Registry statusCompleted

  • Relative Bioavailability Study of GSK1265744 Formulations

    NCT01648257 · start 2012-08

    Registered record
    Registry ID
    NCT01648257
    Conditions
    Infections, Human Immunodeficiency Virus and Hepatitis
    Interventions
    GSK1265744 Na Salt Tablets; GSK1265744 Free Acid Nanomilled Capsules; GSK1265744 Free Acid Micronized Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-08
    Completion
    2012-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Human Immunodeficiency Virus and Hepatitis
    InterventionGSK1265744 Na Salt Tablets; GSK1265744 Free Acid Nanomilled Capsules; GSK1265744 Free Acid Micronized Capsules
    PhasePhase 1
    Registry statusCompleted